AAD 2023: Monoclonal Antibody Treatment Lebrikizumab Safe and Effective for Atopic Dermatitis
Identical phase 3 trials reveal reduced incidence of itch during 16-week period
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.